Medlab Clinical Ltd. updated shareholders on the progress of our NanoCelle® NanaBis program. Researchers at the School of Pharmacy and Medical Sciences at University of South Australia have independently confirmed that NanaBis has two times more bioavailability than an ARTG (Australian Register of Therapeutic Goods) approved oral cannabis (CBD and THC) medicine. This research was conducted using a Population pharmacokinetics (PopPK) study, which examines the variability in drug concentrations within a patient population receiving clinically relevant doses of a drug of interest.

PopPK methods use mathematical models to describe PK data and draw conclusions. Bioavailability is a key indicator of drug absorption and refers to the extent and rate at which the active moiety (drug or metabolite) is absorbed from a drug product and successfully enters systemic circulation, thereby accessing the site of action. The NanoCelle® delivery platform is a patented chemical construct that uses approved (FDA) compounds for the creation of standardised nanoparticles.

Prior work demonstrated a five times bioavailability to other ingested (swallowed) medicines. NanoCelle® represents a central technology that they employ in all primary and secondary drug development programs: PRIMARY Drug Development: NANABIS, cannabinoids (THC & CBD) with FDA recognised API Drug Master Files (DMFs) for proposed indication of Cancer Bone Pain (Bone METs), with line of sight on benefiting larger neuropathic pain populations. SECONDARY Drug Development: NANOCBDTM, cannabinoid (CBD) with a FDA recognised API DMF for proposed indication of Occupational Stress, with line of sight on benefiting mild, chronic pain populations.

MDC2000, proposed FDA 505(b)(2) program using an earlier, approved drug substance for Depression for proposed indication of Major Depressive Disorders. NASAL RNA, Nucleic Acid collaboration with Woolcock Institute at Macquarie University and University of New South Wales in pre-clinical stages for a nasal vaccine delivery utilising nucleic acid, leading to new vaccine and/or anti-viral technologies.